InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
InspireMD (Nasdaq: NSPR) announced that its Compensation Committee approved inducement grants totaling 36,118 restricted shares to one new non-executive employee, granted under the company's 2024 Inducement Plan with a grant date of January 14, 2026.
The awards were made outside the 2021 Equity Incentive Plan as an inducement material to the employee entering employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock vests over three years: one-third on the first anniversary and the remaining two-thirds in equal installments on the second and third anniversaries, subject to continued employment on each vesting date.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NSPR gained 1.26%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.1% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $917K to the company's valuation, bringing the market cap to $74M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NSPR slipped 0.63% while peers were mixed: BDMD -9.45%, PROF -2.03% versus ICAD +3.48%, RCEL +12.39%, SERA +4.57%, indicating stock-specific trading rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Pivotal trial data | Positive | -5.8% | Publication of C-GUARDIANS pivotal trial showing low adverse event rates. |
| Nov 24 | Clinical study news | Positive | +1.6% | CREST-2 data supporting carotid artery stenting benefits over medical therapy alone. |
| Nov 21 | Inducement grants | Positive | +13.5% | Inducement grants of 122,054 restricted shares to new non-executive employees. |
| Nov 19 | Conference participation | Neutral | -2.0% | Announcement of participation in Piper Sandler healthcare conference webcast. |
| Nov 04 | Earnings update | Neutral | -7.2% | Q3 2025 results with revenue growth but higher operating expenses and net loss. |
Recent news shows positive clinical and strategic updates sometimes met with negative price reactions, while an earlier inducement grant announcement coincided with a strong gain.
Over the last few months, InspireMD reported several milestones. On Nov 4, 2025, Q3 2025 results showed 39% revenue growth to $2.5M but a higher net loss, and the stock fell. Later in November, conference participation and inducement grants under Nasdaq rules were announced, with the Nov 21 inducement news seeing a 13.53% gain. Positive carotid stenting data from the CREST-2 study on Nov 24, 2025 produced a modest uptick, while the highly favorable C‑GUARDIANS pivotal publication on Jan 12, 2026 coincided with a -5.81% move, showing occasional divergence between strong clinical data and price.
Regulatory & Risk Context
The company has an active S-3 shelf registration filed on 2025-08-06, expiring 2028-08-06. It is marked as not yet effective and shows 0 recorded usages in the provided data.
Market Pulse Summary
This announcement details a routine inducement grant of 36,118 restricted shares to a new non-executive employee under the 2024 Inducement Plan, vesting over three years per Nasdaq Listing Rule 5635(c)(4). It follows a series of recent updates, including pivotal trial data and Q3 2025 financials. Investors may track how recurring equity awards interact with the existing capital structure and monitor upcoming clinical, commercial, and regulatory milestones highlighted in prior releases.
Key Terms
Nasdaq Listing Rule 5635(c)(4) regulatory
restricted stock financial
equity awards financial
Equity Incentive Plan financial
Inducement Plan financial
AI-generated analysis. Not financial advice.
MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of January 14, 2026, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants were granted under the InspireMD’s 2024 Inducement Plan, which is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock vests over a three-year period, with one-third vesting on the first anniversary of the grant and the remainder vesting in two equal installments on the second and third anniversaries of the grant date, subject to continued employment with InspireMD as of such vesting dates.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the Company’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of its liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; the Company’s need to raise additional capital to meet its business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; the clinical development, commercialization and market acceptance of the Company’s products; whether the clinical trial results for the Company’s products will be predictive of real-world results; an inability to secure and maintain regulatory approvals for the sale of the Company’s products; negative clinical trial results or lengthy product delays in key markets; the Company’s ability to maintain compliance with the Nasdaq listing standards; the Company’s ability to generate significant revenues from its products; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the ongoing commercial launch of its products; the Company’s dependence on a single manufacturing facility and its ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from the Company’s current and planned clinical trials may not be sufficient to demonstrate that its technology is an attractive alternative to other procedures and products; intense competition in the Company’s industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than it does; entry of new competitors and products and potential technological obsolescence of the Company’s products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with the Company’s research and products and potential product liability claims; product malfunctions; price increases for supplies and components; whether access to the Company’s products is achieved in a commercially viable manner and whether its products receive adequate reimbursement by governmental and other third-party payers; the Company’s efforts to successfully obtain and maintain intellectual property protection covering its products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that the Company conducts business in multiple foreign jurisdictions, exposing it to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; security, political and economic instability in the Middle East that could harm the Company’s business, including due to the current security situation in Israel; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; and changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements and the impact of such policies on the Company, its customers and suppliers, and the global economic environment. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com
investor-relations@inspiremd.com
FAQ
What did InspireMD (NSPR) announce on January 20, 2026 about inducement grants?
Under which plan were the InspireMD (NSPR) inducement awards granted?
How do the restricted shares for the new InspireMD (NSPR) employee vest?
Why did InspireMD (NSPR) issue inducement grants outside its 2021 equity plan?
Does the Inspir eMD (NSPR) announcement state the number of employees receiving inducement shares?
What employment condition is required for vesting of the InspireMD (NSPR) restricted stock?
